Contributions
Type: Publication Only
Background
Recent reports identify the ratio between absolute neutrophils count (ANC) and absolute lymphocyte count (ALC), called NLR,as predictor of progression free survival (PFS) and overall survival (OS) in cancer patients.
Aims
We retrospectively tested NLR in a cohort of 309 newly diagnosed MM patients treated upfront with novel agents.
Methods
NLR was calculated using data obtained from the complete blood count (CBC). PFS and OS were evaluated.
Results
Median NLR was 1.9 (range 0.4-15.9). Higher NLR was not due to ISS stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2% and 36.4% for patients with NLR ≥ 2 versus 25.5% and 66.6% in patients with NLR < 2.
NLR ≥ 2 reduced PFS for ISS stage I and OS significantly for stages I and III, but not stage II.
Among younger patients (age <65 years, N=179), NLR ≥ 2 had a negative prognostic impact on both PFS and OS, in all ISS stages. By combining ISS stage and NLR in a model limited to young patients, we found that 19% of the patients were classified as very-low risk group, and 70% and 11% were in standard-risk and very-high risk groups, respectively. The 5-year estimates were 39.3%, 19.4% and 10.9% for PFS and 95.8%, 50.9% and 23.6% for OS for low, standard and high risk groups, respectively.
Summary
We found NLR as predictor of PFS and OS in MM patients treated upfront with novel agents. NLR can be combined with ISS staging system allowing a better identification of patients with dismal outcome.
Keyword(s): Multiple myeloma, Neutrophil, Staging
Session topic: Publication Only
Type: Publication Only
Background
Recent reports identify the ratio between absolute neutrophils count (ANC) and absolute lymphocyte count (ALC), called NLR,as predictor of progression free survival (PFS) and overall survival (OS) in cancer patients.
Aims
We retrospectively tested NLR in a cohort of 309 newly diagnosed MM patients treated upfront with novel agents.
Methods
NLR was calculated using data obtained from the complete blood count (CBC). PFS and OS were evaluated.
Results
Median NLR was 1.9 (range 0.4-15.9). Higher NLR was not due to ISS stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2% and 36.4% for patients with NLR ≥ 2 versus 25.5% and 66.6% in patients with NLR < 2.
NLR ≥ 2 reduced PFS for ISS stage I and OS significantly for stages I and III, but not stage II.
Among younger patients (age <65 years, N=179), NLR ≥ 2 had a negative prognostic impact on both PFS and OS, in all ISS stages. By combining ISS stage and NLR in a model limited to young patients, we found that 19% of the patients were classified as very-low risk group, and 70% and 11% were in standard-risk and very-high risk groups, respectively. The 5-year estimates were 39.3%, 19.4% and 10.9% for PFS and 95.8%, 50.9% and 23.6% for OS for low, standard and high risk groups, respectively.
Summary
We found NLR as predictor of PFS and OS in MM patients treated upfront with novel agents. NLR can be combined with ISS staging system allowing a better identification of patients with dismal outcome.
Keyword(s): Multiple myeloma, Neutrophil, Staging
Session topic: Publication Only